Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialSherene Loi, Christos Sotiriou, Stefan Michiels et al.|Annals of Oncology|2014Cited by 1.3k
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupM.F. Mosele, Fabrice André, C. Benedikt Westphalen et al.|Annals of Oncology|2024Cited by 343
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysisFrançois‐Clément Bidard, Paul Cottu, Carolyn Hall et al.|JNCI Journal of the National Cancer Institute|2018Cited by 282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paperMassimo Cristofanilli, Klaus Pantel, Jean‐Yves Pierga et al.|Critical Reviews in Oncology/Hematology|2018Cited by 268
Predictors of responses to immune checkpoint blockade in advanced melanomaNicolas Jacquelot, Laurence Zitvogel, María P. Roberti et al.|Nature Communications|2017Cited by 201